Helping Alzheimers, Parkinson’s Patients: Sen. Gillibrand Announces Introduction Of Promising Pathway Act, Accelerating FDA Approval For New Drugs For Life Threatening Illnesses

GILLIBRAND TO HOLD PRESS CONFERENCE TO DISCUSS LEGISLATION TO ACCELERATE PROVISIONAL FDA APPROVAL OF DRUGS TO TREAT LIFE-THREATENING ILLNESSES

WASHINGTON, D.C. — U.S. Senator Kirsten Gillibrand will hold a press conference to discuss her bipartisan legislation to expedite provisional FDA approval of drugs intended to treat ALS, Parkinson’s, Alzheimer’s, and other life-threatening diseases.

The standard FDA approval process takes years to get drugs to market, but patients with rapidly progressing illnesses often don’t have years to wait.

Gillibrand’s Promising Pathway Act would create a provisional approval pathway and help get promising treatments to those who need them.

Gillibrand will be joined by Senator Mike Braun (R-IN) and Representative Mike Quigley (D-IL).

The press conference will be livestreamed on Senator Gillibrand’s Facebook page.

Banner Image: Elderly woman. Image Credit – Gadini

Senator Kirsten Gillibrand